Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 15/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL27578786 | 0.88 | AOC3 (0.78) | AOC3L3MBTL1 | |
| Fumaric Acid SCHEMBL27578785 | 0.88 | AOC3 (0.78) | AOC3L3MBTL1 | |
| SCHEMBL6743030 | 0.81 | AOC3 (0.68) | AOC3L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL7066459 | 0.80 | AOC3 (1.00) | AOC3 | |
| SCHEMBL4032416 | 0.80 | AOC3 (0.67) | AOC3L3MBTL1 | |
| SCHEMBL19217778 | 0.77 | AOC3 (0.62) | AOC3L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL14402423 | 0.76 | AOC3 (0.60) | AOC3L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL13516902 | 0.74 | AOC3 (0.59) | AOC3L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL27228369 | 0.74 | AOC3 (0.59) | AOC3L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL11468299 | 0.74 | AOC3 (0.59) | AOC3L3MBTL1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106654-A1 | Inhibitors of copper-containing amine oxidases | SMITH DAVID JOHN (FI) | 2004-06-03 | — | — | US | claimed |
| US-20020173521-A1 | Inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORP. | 2002-11-21 | — | — | US | claimed |
| US-20040106654-A1 | Inhibitors of copper-containing amine oxidases | SMITH DAVID JOHN (FI) | 2004-06-03 | — | — | US | disclosed |
| US-6624202-B2 | Antiinflammatory agents; antiarthritic agents; skin disorders | BIOTIE THERAPIES CORP. (FI) | 2003-09-23 | — | — | US | disclosed |
| US-20020173521-A1 | Inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORP. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106654-A1 | Inhibitors of copper-containing amine oxidases | VCAM1, AOC3, AOC2 | AOC3 2/4885L3MBTL1 3995/4885SLC6A2 291/4885 |
| US-20020173521-A1 | Inhibitors of copper-containing amine oxidases | VCAM1, AOC3, AOC2 | AOC3 2/4885L3MBTL1 3995/4885SLC6A2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.